Approval · Notice of Compliance 25217 · 2021
TASIGNA: Notice of Compliance 25217
Issued February 16, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25217
- Date
- February 16, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the package insert aw wellas inner and outer labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TASIGNA | Not yet assigned | — |
Medicinal ingredients
- NILOTINIB HYDROCHLORIDE MONOHYDRATE 50 MG per CAP
- NILOTINIB HYDROCHLORIDE MONOHYDRATE 150 MG per CAP
- NILOTINIB HYDROCHLORIDE MONOHYDRATE 200 MG per CAP